Filing Overview
This Form 8-K was filed by Galecto, Inc. on June 17, 2022, reporting matters from its annual meeting of stockholders held June 14, 2022. The request metadata identifies Damora Therapeutics, Inc., but the filing names Galecto, Inc. as the registrant.
Business Context and Reporting Period
The filing concerns corporate governance and auditor approval under Item 5.07. Galecto’s common stock trades on Nasdaq under the symbol GLTO. The company identified itself as an emerging growth company.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics.
Material Developments
- All matters submitted to stockholders were approved.
- Carl Goldfischer, M.D., and David Shapiro, M.D., were elected as Class II directors to serve until the 2025 annual meeting, subject to earlier death, resignation, removal, or replacement.
- Stockholders ratified EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Voting Results
| Proposal | For | Against/Withheld | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Carl Goldfischer election | 11,025,408 | 1,261,776 withheld | Not separately stated | 3,360,631 |
| David Shapiro election | 11,050,440 | 1,236,744 withheld | Not separately stated | 3,360,631 |
| Auditor ratification | 15,589,293 | 33,022 | 25,500 | None |
Of 25,261,832 shares entitled to vote, 15,647,815 shares were present or represented by valid proxy.
Guidance, Risks, and Unusual Items
The filing provides no financial guidance, risk updates, contingencies, or unusual financial items. It indicates that the auditor appointment applies to the fiscal year ending December 31, 2022.
Investor Verification Checklist
- Verify the registrant identity: the filing is for Galecto, Inc., not Damora Therapeutics, Inc.
- Review the company’s proxy statement filed April 28, 2022 for proposal details and director information.
- Confirm the elected directors’ terms and the ratified auditor appointment.
- Consult the company’s periodic reports for financial performance, liquidity, capital resources, and business outlook, none of which are included in this 8-K.